Please login to the form below

Not currently logged in

Eli Lilly promotes Anat Ashkenazi to chief financial officer

Ashkenazi previously served as CFO of Lilly Research Laboratories

Eli Lilly has appointed Anat Ashkenazi (pictured above) as chief financial officer (CFO) and senior vice president of the company.

Most recently, Ashkenazi served as senior vice president, controller and CFO of Lilly Research Laboratories.

She has worked at Lilly for almost 20 years, having served in her most recent role at Lilly Research Laboratories since 2016.

In this role, Ashkenazi oversaw the CFOs of the company’s commercial businesses and those for research and development, manufacturing and quality and G&A functions.

During this time, she also led the corporate strategic planning team and business transformation office.

Prior to this, she served as CFO for across a number of Lilly’s global business areas.

"We are confident in Anat's ability to serve as our next CFO given her impeccable track record of leadership and business success across nearly all major parts of the company, most recently as corporate controller and head of strategy,” said David Ricks, chairman and chief executive officer of Lilly.

Ashkenazi succeeds Josh Smiley in the CFO role, who has resigned from the post and is set to leave the company.

Article by
Lucy Parsons

10th February 2021

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...